Needle-Free Delivery: Technology and Market Forecast 2014-2024

LONDON, April 11, 2014 /PRNewswire/ --

Needle-free delivery - discover technological and commercial prospects 

What does the future hold for the needle-free delivery market? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 187 page report provides 103 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Robert E. Sievers, CEO and President, Aktiv-Dry LLC
- David Hoey, CEO, Vaxxas
- Professor Mark Kendall, Inventor of the Nanopatch and Co-Founder of Vaxxas
- John Turanin, Vice President and General Manager, Zogenix Technologies
- Mark Logomasini, President and CEO, Bioject Medical Technologies

You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of two world-level submarkets to 2024:
• Jet injectors market
• Competing needle-free technology market
 
The competing needle-free technology market is further segmented into:
• Novel needle technology (includes microneedles and pen needles)
• Inhaler technology
• Patch technology
 
Our investigation shows business research and analysis with individual revenue forecasts and discussions. How will those needle-free technologies expand? Which applications will generate most money? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

What are the prospects in the leading regions and countries?
Events and progress worldwide will influence the market. In our study you will find individual revenue forecasts to 2024 for 10 national markets:
• US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• China
• India
• Row

Many opportunities exist within the needle-free delivery market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Leading companies and potential for market growth
Overall world revenue for the needle-free delivery market will reach $1.2bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
• Antares Pharma
• Zogenix
• Bioject Medical Technologies
• 3M
• Medical International Technology (MIT)
• D'Antonio Consultants International (DCI)
• PharmaJet
• Akra Dermojet
• Injex Pharma
• Glide Pharma

In general, a company profile gives you the following information:
• Overview of the company, including its history in the market
• Discussion of a company's activities and outlook including descriptions of leading products
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

What issues will affect the needle-free delivery market?
Our new report discusses issues and events affecting the needle-free delivery market. You will find discussions, including qualitative analyses:
• Developments in transdermal delivery
• Growing demand for minimally invasive delivery methods
• Mass immunisation programmes across the globe
• Booming global vaccine market
• Shift towards home administration settings
• Increasing regulatory scrutiny
• Inefficient manufacturing processes leading to costly needle-free technologies
 
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Needle-Free Delivery: Technology and Market Forecast 2014-2024 & Prospects for Leading Companies report helps you

In summary, our 187 page report gives you the following knowledge:
• Revenues forecasts to 2024 for the overall world needle-free delivery market, 2 submarkets and 3 leading segments - discover the industry's prospects, finding promising places for investments and revenues
• Assessment of 10 leading companies, and others, discovering activities and outlooks
• Market forecasting to 2024 for 10 leading regions and countries - USA, Japan, Germany, France, UK, Spain, Italy, Rest of Europe, India, China and RoW
• View opinions from our survey, seeing 5 interviews with leading authorities
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the needle-free delivery market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the needle-free delivery market. You find data, trends and predictions. Please order our report now.

To request a report overview please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1236/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024

Companies Listed in this report: 

Companies Listed
3M
4P
Therapeutics
Activa Brand Products
AcuShot
Akra Dermojet
AKTIV-DRY
Alkermes
Allen & Hanburys
AllTranz
Altea Development Corporation
Altus Formulation
ALZA Pharmaceuticals
Amerisource Bergen Corporation
Anesiva
Antares Pharma
Aradigm
Astellas Pharma
AstraZeneca
B Braun
Battelle
Becton Dickinson
Berlex Laboratories
Bespak
Bioject Medical Technologies
Boehringer Ingelheim
Bristol-Myers Squibb
Cambridge Consultants
Cardinal Health Inc.
Corium International
Covidien
Crossject Medical Technology
CSL Behring
CSL Limited
CVS Pharmacy (CVS.com)
Cydex (subsidiary by Ligand)
Cyto Pulse Sciences
D'Antonio Consultants International
Daewoong Pharmaceuticals
Debiotech
Dr. Reddy's Laboratories
Durect
Echo Therapeutics
Eli Lilly
Eloquest Healthcare
EMD Serono (subsidiary MERCK KGAA)
Endo Pharmaceuticals
Eternity Healthcare
Ethical Holdings
Eurojet Medical
Evonik Industries
Felton International
Ferndale Pharma Group
Ferring
Generex
GlaxoSmithKline
Glide Pharma
Hangzhou Hema Medical equipment Co. Ltd
Injex Pharma
Intercell
IOMAI
Janssen Pharmaceuticals
JCR Pharmaceuticals
Jiangsu Hualan MIT Medical Technology (MIT China)
Johnson and Johnson
Key Pharmaceuticals
Kroger
Mallinckrodt Pharmaceuticals
MannKind
McKesson Corporation
MEDA
Medical House Products Limited
Medical International Technologies
MEDICI Ltd.
MedImmune
Merck Sorono
MGlas AG
Mystic Pharmaceuticals
nanoBioSciences
NanoPass Technologies
Napp Pharmaceuticals
National Medical Products
Nektar Therapeutics
Neumaura Pharma
Nicobrand Limited
Novartis
Novo Nordisk
Novogyne Pharmaceuticals
Nycomed
Nypro Limited
Owen Mumford
Pantec Biosolutions
Parke-Davis
Patheon UK
PenJet Corporation
Pfenex
Pfizer
Pharmacia & Upjohn
PharmaJet
Philips Medical
PKA SoftTouch Corp
PowderJect Pharmaceuticals (subsidiary of Pfizer)
PowerMed (acquired by Pfizer)
Procter and Gamble
ProStrakan
Pulse Needle-free Systems
Purdue Pharma
Sanofi
Schering
Schuco
Schwarz Pharma
Serum Institute of India
Shire
Shwarz-Pharma
 Somerset Pharmaceuticals
Spruyt hillen
STAT Medical Devices
Syke Pharma
Syneron
Taizhou Amazon Investment Center
Takeda
Tapemark
Team Consulting
Teva Pharmaceutical
The Medicines Company
TheraJect
TheraTech
Trinity-Chiesi
UCB
Valeant
Valeritas
VAXXAS
Vygon
Vyteris
Watson Pharmaceuticals
Ypsomed Holiding
Zeltrix
Zogenix
Zosano Pharma
Zydus Cadil

Other Organisations Mentioned in This Report
Ankara University
Australian Institute of Bioengineering and Nanotechnology, University of Queensland
Biomedicine International
CDC Measles Eradication Committee
Center for Biologics Evaluation and Research (CBER) (US)
Center for Drug Evaluation and Research (CDER) (US)
Centers for Disease Control and Prevention (CDC)
Echo Therapeutics
Emory University
European Union (EU)
European Union Council
Gates Foundation
Georgia Tech's School of Chemical and Biomolecular Engineering
Gwangju Institute of Science and Technology
Harvard University
Indian Institute of Science
Karolinska Institutet
Leiden University Medical Centre
Massachusetts Institute of Technology (MIT)
Medical Products Agency (Sweden)
Medicine In Need (MEND)
MPI Research
National Competent Authorities (NCAs)
National Health Services (NHS)
National Institute of Health (NIH)
Population Council
Royal College of Nursing (RCN)
Seoul National University
The Accidental Blood Exposure Study Task Force (GERES) (France)
The Centre for Devices and Radiological Health (CDRH)
The China Food and Drug Administration (CFDA) (China)
The China State Food and Drug Administration (SFDA) (China)
The Food and Drug Administration (FDA) (US)
The Global Polio Eradication Initiative (GPEI)
The International Diabetes Federation (IDF)
The Ministry of Health of Oman
The Ministry of Health, Labour, and Welfare (MHLW)
The National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Health (NIH)
The Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)
The Program for Appropriate Technology in Health (PATH)
The Swedish Institute for Infectious Disease Control
The University of Colorado Cooperative Institute for Research in Environmental Sciences (CIRES)
The US Army Medical Research Institute of Infectious Diseases (USAMRIID)
U.S. Navy
University Erlangen-Nurnberg
University of California
University of Colorado
University of Oxford
US Military
World Health Organisation (WHO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com